Kymera Therapeutics, Inc. Common Stock Earnings Dividend

Kymera Therapeutics, Inc. Common Stock’s revenue jumped 466.4% since last year same period to $65Mn in the Q2 2026. On a quarterly growth basis, Kymera Therapeutics, Inc. Common Stock has generated 89.15% jump in its revenue since last 3-months.

Kymera Therapeutics, Inc. Common Stock’s net profit jumped 20.1% since last year same period to $-61.21Mn in the Q2 2026. On a quarterly growth basis, Kymera Therapeutics, Inc. Common Stock has generated 11.59% jump in its net profits since last 3-months.

Kymera Therapeutics, Inc. Common Stock’s net profit margin jumped 85.89% since last year same period to -94.17% in the Q2 2026. On a quarterly growth basis, Kymera Therapeutics, Inc. Common Stock has generated 53.26% jump in its net profit margins since last 3-months.

Kymera Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.25 - a -95.31% fall from last quarter’s estimates.

Kymera Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.25.

Kymera Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 34.74% since last year same period to -0.62 in the Q2 2026. This indicates that the Kymera Therapeutics, Inc. Common Stock has generated 34.74% annual rate of jump in its earning per share (EPS) in the last 4 quarters.